Stock Scorecard



Stock Summary for Zymeworks BC Inc (ZYME) - $10.30 as of 3/27/2024 9:44:44 PM EST

Total Score

9 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ZYME

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ZYME

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ZYME

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for ZYME

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for ZYME

$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying 1/24/2023 2:15:00 PM
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying 1/19/2023 12:17:00 PM
Around $8 Million Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying - Comtech Telecom ( NASDAQ:CMTL ) , Alvarium Tiedemann Hldgs ( NASDAQ:ALTI ) 1/13/2023 11:31:00 AM
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline - Zymeworks BC ( NYSE:ZYME ) 10/21/2022 5:35:00 PM
Zymeworks ( ZYME ) Up on Licensing Deal With Jazz Pharmaceuticals 10/20/2022 5:36:00 PM
Zymeworks Inc. ( ZYME ) Surges 15.9%: Is This an Indication of Further Gains? 10/20/2022 3:48:00 PM
Intuitive Surgical, Netflix, ASML And Other Big Gainers From Wednesday - Amprius Technologies ( NYSE:AMPX ) , ASML Holding ( NASDAQ:ASML ) 10/20/2022 8:39:00 AM
Why Zymeworks Stock Is Soaring Today 10/19/2022 3:08:00 PM
Why Zymeworks ( ZYME ) Shares Are Trading Higher Premarket Today - Jazz Pharmaceuticals ( NASDAQ:JAZZ ) , Zymeworks ( NYSE:ZYME ) 10/19/2022 11:29:00 AM
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody 10/19/2022 10:00:00 AM

Financial Details for ZYME

Company Overview

Ticker ZYME
Company Name Zymeworks BC Inc
Country USA
Description Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date N/A

Stock Price History

Last Day Price 10.30
Last Day Price Updated 3/27/2024 9:44:44 PM EST
Last Day Volume 398,744
Average Daily Volume 570,059
52-Week High 13.14
52-Week Low 6.01
Last Price to 52 Week Low 71.38%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -6.32
Free Cash Flow Ratio 1.94
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 7.41
Total Cash Per Share 5.30
Book Value Per Share Most Recent Quarter 6.63
Price to Book Ratio 1.58
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 9.72
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 70,568,000
Market Capitalization 726,850,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -195.44%
Reported EPS 12 Trailing Months -1.72
Reported EPS Past Year -1.73
Reported EPS Prior Year 1.93
Net Income Twelve Trailing Months -118,674,000
Net Income Past Year -118,674,000
Net Income Prior Year 124,341,000
Quarterly Revenue Growth YOY -95.80%
5-Year Revenue Growth -81.91%

Balance Sheet

Total Cash Most Recent Quarter 374,327,000
Total Cash Past Year 374,327,000
Total Cash Prior Year 492,232,000
Net Cash Position Most Recent Quarter 374,327,000
Net Cash Position Past Year 374,327,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 464,806,000
Total Stockholder Equity Prior Year 492,956,000
Total Stockholder Equity Most Recent Quarter 464,806,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.21
MACD Signal -0.05
20-Day Bollinger Lower Band 7.54
20-Day Bollinger Middle Band 10.23
20-Day Bollinger Upper Band 12.92
Beta 1.15
RSI 42.80
50-Day SMA 8.79
200-Day SMA 19.39

System

Modified 3/27/2024 11:14:57 AM EST